Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase

Juliya Kalinina, Jun Ahn, Narra S. Devi, Liya Wang, Yuancheng Li, Jeffrey J. Olson, Michael Glantz, Thomas Smith, Ella L. Kim, Alf Giese, Randy L. Jensen, Clark C. Chen, Bob S. Carter, Hui Mao, Miao He, Erwin G. Van Meir

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Purpose: Elevation in D-2-Hydroxyglutarate (D-2HG) has recently emerged as a mandatory byproduct of mutated Isocitrate Dehydrogenase (IDH) genes 1 and 2 in glioma patients. The goal of the present study was to demonstrate the feasibility of detection of elevated levels of D-2HG in the cerebrospinal fluid (CSF) of glioma patients that carry point substitutions in the IDH gene. Experimental Design: We developed a mass spectrometry (MS)-based platform to detect and quantify the D- and L-forms of 2HG in the CSF of glioma patients. Three independent cohorts of patients were analyzed, comprising a total of 176 samples derived from 84 patients. The levels of D- and L-2HG were used to stratify patients into IDH wild-type or IDH-mutated groups using an empirically obtained threshold of 0.69 μmol/L. Results: Using this platform, a greater than 17-fold mean increase in D-2HG was observed in the CSF of patients with IDH mutant versus wild-type gliomas. The means for the D-2HG levels in CSF were 0.427 μmol/L in wild-type and 7.439 μmol/L in mutant groups. The C statistic for the receiver operator curve was 0.938, with 84% sensitivity, 90% specificity, and 89% accuracy to detect D-2HG. The levels of D- and L-2HG in CSF from wild-type patients varied by location of CSF draw (cisternal>ventricular>lumbar). Conclusions: Our findings demonstrate that the CSF of patients harboring IDH mutant gliomas contain increased levels of D-2HG, which can be reliably detected with a MS-based platform.

Original languageEnglish (US)
Pages (from-to)6256-6265
Number of pages10
JournalClinical Cancer Research
Volume22
Issue number24
DOIs
StatePublished - Dec 15 2016

Bibliographical note

Funding Information:
J.J. Olson reports receiving commercial research grants from Genentech and Millennium and other commercial research support from Merck. R.L. Jensen is a consultant/advisory board member for Medtronic, Pharmacokinesis, and Varian. No potential conflicts of interest were disclosed by the other authors. We thank Narra Sarojini Devi, Milton Merchant, Lawrence Recht and Zhaobin Zhang for help with patient sample banking. This work was supported in part by grants from the NIH (CA086335, CA116804, NS096236 to E.G. Van Meir, CA169937 to H. Mao, CA138292 to Walter Curran, Winship Cancer Institute), NINDS training grant 2T32NS007480-11 (to J. Kalinina and Allan I. Levey), the Brain Tumor Funders Collaborative (to E.G. Van Meir), and the Georgia Cancer Coalition (to J. Kalinina and E.G. Van Meir). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Publisher Copyright:
©2016 AACR.

Fingerprint

Dive into the research topics of 'Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase'. Together they form a unique fingerprint.

Cite this